ALLEN, Texas, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ: ATRI) today announced that its Board of Directors declared a quarterly dividend of $2.20 per share on its outstanding shares of Common Stock. This dividend will be payable on March 29, 2024 to stockholders of record at the close of business on March 15, 2024.
Atrion Corporation develops and manufactures products primarily for medical applications. The Company’s website is www.atrioncorp.com.
| Contact: | Cindy Ferguson Vice President and Chief Financial Officer (972) 390-9800 | |
| Last Trade: | US$459.92 |
| Daily Volume: | 0 |
| Market Cap: | US$809.460M |
August 08, 2024 May 28, 2024 May 10, 2024 February 29, 2024 November 07, 2023 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
